Por favor, use este identificador para citar o enlazar este ítem: https://hdl.handle.net/11000/33766
Registro completo de metadatos
Campo DC Valor Lengua/Idioma
dc.contributor.authorFernandez-Diaz, Eva-
dc.contributor.authorPerez-Vicente, Jose A.-
dc.contributor.authorVILLAVERDE GONZALEZ, RAMON-
dc.contributor.authorBerenguer Ruiz, Leticia-
dc.contributor.authorCandeliere Merlicco, Antonio-
dc.contributor.authorMartinez-Navarro, Maria Luisa-
dc.contributor.authorGracia Gil, Julia-
dc.contributor.authorRomero-Sanchez, Carlos M.-
dc.contributor.authorAlfaro Sáez, Arantxa-
dc.contributor.authorDiaz, Inmaculada-
dc.contributor.authorGimenez‑Martinez, Juana-
dc.contributor.authorMendez-Miralles, Maria Angeles-
dc.contributor.authorMillan-Pascual, Jorge-
dc.contributor.authorJimenez-Pancho, Javier-
dc.contributor.authorMola, Santiago-
dc.contributor.authorSempere, Angel P.-
dc.contributor.otherDepartamentos de la UMH::Medicina Clínicaes_ES
dc.date.accessioned2024-11-04T10:27:27Z-
dc.date.available2024-11-04T10:27:27Z-
dc.date.created2021-
dc.identifier.citationAnnals of Clinical and Translational Neurology 2021; 8(2): 385–39es_ES
dc.identifier.issn2328-9503-
dc.identifier.urihttps://hdl.handle.net/11000/33766-
dc.description.abstractObjective: Pivotal trial have shown that patients with multiple sclerosis (MS) receiving ocrelizumab had better outcomes. However, data on ocrelizumab in clinical practice are limited. The aim of this study was to evaluate the preliminary safety profile and effectiveness of ocrelizumab treatment for multiple sclerosis (MS) in a real-world clinical setting. Methods: We conducted a retrospective study including consecutive patients from nine public hospitals in south-eastern Spain who received ocrelizumab after it was approved. Results: A total of 228 MS patients were included (144 with relapsing–remitting MS [RRMS], 25 secondary progressive MS [SPMS], and 59 primary progressive MS [PPMS]). Median follow-up period was 12 months (range, 1-32). No evidence of disease activity (NEDA) status at year 1 was achieved in 91.2% of the relapsing MS (RMS) population, while disability progression was detected in 37.5% of the PPMS patients (median follow-up period, 19 months). The most common adverse events reported were infusion-related reactions and infections, with the most common infections being urinary tract infections followed by upper respiratory infections and COVID-19. Interpretation: The preliminary results in our real-world setting show that ocrelizumab presented excellent results in suppressing disease activity with a favorable and consistent safety profile.es_ES
dc.formatapplication/pdfes_ES
dc.format.extent10es_ES
dc.language.isoenges_ES
dc.publisherWiley Periodicals LLCes_ES
dc.rightsinfo:eu-repo/semantics/openAccesses_ES
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectEsclerosis múltiplees_ES
dc.subjectocrelizumabes_ES
dc.subject.otherCDU::6 - Ciencias aplicadas::61 - Medicinaes_ES
dc.titleReal-world experience of ocrelizumab in multiple sclerosis in a Spanish populationes_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.relation.publisherversionhttps://doi.org/10.1002/acn3.51282es_ES
Aparece en las colecciones:
Artículos Medicina Clínica


Vista previa

Ver/Abrir:
 Real-world experience of ocrelizumab in multiple sclerosis.pdf

351,03 kB
Adobe PDF
Compartir:


Creative Commons La licencia se describe como: Atribución-NonComercial-NoDerivada 4.0 Internacional.